2022年中國醫保基金支付核酸檢測費43億人幣
國家醫療保障局發表統計快報顯示,2022年中國醫保基金支付核酸檢測費用43億元人民幣(下同)。2021年至2022年累計結算新冠病毒疫苗及接種費用逾1,500億元。
統計顯示,牽頭與疫苗生產企業開展價格磋商,滅活疫苗、重組蛋白疫苗及腺病毒載體疫苗三種技術路線的單支單劑價格,基準統一為約16元。核酸檢測單人單檢每人份價格不高於16元,多人混檢每人份價格不高於5元,大規模檢測每人份降至3.5元以下,抗原檢測「項目價格+檢測試劑」收費不高於每人份6元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.